Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Downgrades Casper Sleep to Neutral

Wedbush analyst Seth Basham downgrades Casper Sleep (NYSE:CSPR) from Outperform to Neutral.

byBenzinga Newsdesk

October 25, 2021

1 minute read

Wedbush analyst Seth Basham downgrades Casper Sleep (NYSE:CSPR) from Outperform to Neutral.

Citigroup Maintains Neutral on Live Nation Entertainment, Raises Price Target to $98

By Benzinga Newsdesk

Today, 2:00 AM

Citigroup maintains Live Nation Entertainment (NYSE:LYV) with a Neutral and raises the price target from $94 to $98.

LYV

MiX Telematics, Ford Pro Intelligence Bond To Optimize Road Safety, Efficiency

By Anusuya Lahiri

Today, 2:00 AM

MiX Telematics Ltd (NYSE:MIXT) collaborated with Ford Motor Co’s (NYSE:F) Ford Pro Intelligence to provide MiX North America customers operating Ford vehicles…

Analyst Ratings

Analyst Ratings For Boeing

By Benzinga Insights

Today, 2:00 AM

Within the last quarter, Boeing (NYSE:BA) has observed the following analyst ratings:

FDA
News

Galmed Pharmaceuticals Says FDA Agrees With Co’s Plan To Use Aramchol Meglumine In Randomized Double-Blind Placebo-Controlled Part Of Phase 3 ARMOR Study

By Benzinga Newsdesk

Today, 2:00 AM

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed

GLMD

Wedbush Downgrades Casper Sleep to Neutral

Related Posts

Citigroup Maintains Neutral on Live Nation Entertainment, Raises Price Target to $98

MiX Telematics, Ford Pro Intelligence Bond To Optimize Road Safety, Efficiency

Analyst Ratings For Boeing

Galmed Pharmaceuticals Says FDA Agrees With Co’s Plan To Use Aramchol Meglumine In Randomized Double-Blind Placebo-Controlled Part Of Phase 3 ARMOR Study